Bio-Thera Solutions, Ltd. (SHA:688177)

Market Cap	10.84B
Revenue (ttm)	788.13M
Net Income (ttm)	-484.68M
Shares Out	414.08M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	93.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,419,623
Average Volume	3,966,625
Open	27.31
Previous Close	27.11
Day's Range	26.33 - 27.57
52-Week Range	17.70 - 30.38
Beta	0.40
RSI	56.72
Earnings Date	Aug 21, 2025

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. The company offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 1,251
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688177

Financial Performance

In 2024, Bio-Thera Solutions's revenue was 743.17 million, an increase of 5.44% compared to the previous year's 704.79 million. Losses were -510.30 million, 29.3% more than in 2023.